Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CUPM | ISIN: US00449L1026 | Ticker-Symbol: 698
Tradegate
14.11.24
19:19 Uhr
1,030 Euro
+0,065
+6,74 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACHILLES THERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
ACHILLES THERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,9901,03023:00
1,0001,02022:00
GlobeNewswire (Europe)
50 Leser
Artikel bewerten:
(0)

Achilles Therapeutics PLC: Achilles Therapeutics Reports Third Quarter 2024 Financial Results

Finanznachrichten News

- Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 -

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates.

Corporate Updates

  • Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has engaged BofA Securities as a financial advisor in the process of exploring strategic options.
  • Achilles Chief Scientific Officer, Sergio Quezada, presented "Targeting Clonal Neoantigens with Precision T-Cell Therapies: Key Mechanistic Insights From cNeT Clinical Trials" in a seminar on October 23, 2024 at the 6th Annual TIL Therapies Summit.

Financial Highlights

  • Cash and cash equivalents: Cash and cash equivalents were $86.1 million as of September 30, 2024, as compared to $131.5 million as of December 31, 2023. Subsequent to September 30, 2024, the Company received a cash R&D tax credit of $12.8 million.
  • Research and development (R&D) expenses: R&D expenses were $16.4 million for the third quarter ended September 30, 2024, compared to $14.7 million for the third quarter ended September 30, 2023.
  • General and administrative (G&A) expenses: G&A expenses were $4.0 million for the third quarter ended September 30, 2024, compared to $4.4 million for the third quarter ended September 30, 2023.
  • Net loss: Net loss for the third quarter ended September 30, 2024 was $19.6 million or $0.48 per share, compared to $16.7 million or $0.42 per share for the third quarter ended September 30, 2023.

About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company that was developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUSTM bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.

Forward Looking Statements

This press release contains express or implied forward-looking statements that are based on the Company management's belief and assumptions and on information currently available to the Company's management. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company's clinical trials and the Company's beliefs about its goals for the discontinued trials; expectations related to the Company's cash runway and operating expenses and capital expense requirements; the Company's ability to engage with third parties who are developing alternative modalities to target clonal neoantigens for the treatment of cancers and the Company's review and evaluation of potential strategic options and their impact on stockholder value. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or the Company's future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent the Company's views as of the date of this press release. We anticipate that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release.

For further information, please contact:

Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

ACHILLES THERAPEUTICS PLC
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
September 30, December 31,
2024 2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$86,052 $131,539
Prepaid expenses and other current assets 25,573 14,094
Total current assets 111,625 145,633
Property and equipment, net 5,827 9,171
Operating lease right of use assets 3,407 4,372
Deferred tax assets 41 41
Restricted cash 20 33
Other assets 1,756 2,206
Total non-current assets 11,051 15,823
Total assets$122,676 $161,456
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable$ 4,248 $5,629
Accrued expenses and other liabilities 10,602 7,828
Operating lease liabilities - current 3,620 3,539
Total current liabilities 18,470 16,996
NON-CURRENT LIABILITIES:
Operating lease liabilities - non-current - 1,076
Other long-term liability 1,068 1,015
Total non-current liabilities 1,068 2,091
Total liabilities 19,538 19,087
Commitments and contingencies
SHAREHOLDERS' EQUITY:
Ordinary shares, £0.001 par value; 41,100,040 and 41,082,948 shares authorized, issued and outstanding at September 30, 2024 and December 31, 2023, respectively 54 54
Deferred shares, £92,451.85. par value, one share authorized, issued and outstanding at September 30, 2024 and December 31, 2023, respectively 128 128
Additional paid in capital 419,098 415,210
Accumulated other comprehensive income (7,941) (13,071)
Accumulated deficit (308,201) (259,952)
Total shareholders' equity 103,138 142,369
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$122,676 $161,456
ACHILLES THERAPEUTICS PLC

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
Three Months Ended Nine Months Ended
September 30, September 30,
2024 2023 2024 2023
OPERATING EXPENSES:
Research and development$16,396 $14,712 $40,171 $42,354
General and administrative 4,021 4,384 $12,344 13,387
Total operating expenses 20,417 19,096 52,515 55,741
LOSS FROM OPERATIONS: (20,417) (19,096) (52,515) (55,741)
OTHER INCOME (EXPENSE), NET:
Other income (expense) 817 2,389 4,246 4,692
Total other income (expense), net 817 2,389 4,246 4,692
Loss before income taxes (19,600) (16,707) (48,269) (51,049)
Benefit for income taxes 5 24 20 14
Net loss (19,595) (16,683) (48,249) (51,035)
Other comprehensive (loss) income:
Foreign exchange translation adjustment 6,074 (5,289) 5,130 2,505
Comprehensive loss$(13,521) $(21,972) $(43,119) $(48,530)
Net loss per share attributable to ordinary shareholders-basic and diluted$(0.48) $(0.42) $(1.20) $(1.28)
Weighted average ordinary shares outstanding-basic and diluted 40,427,199 40,066,922 40,355,124 39,900,910

© 2024 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.